Efficacy of remission-induction regimens for ANCA-associated vasculitis

New England Journal of Medicine

Volumn 369, Issue 5, 2013, Pages 417-427

  Specks, Ulrich ^a   Merkel, Peter A ^b   Seo, Philip ^d   Spiera, Robert ^g   Langford, Carol A ^h   Hoffman, Gary S ^h   Kallenberg, Cees G M ⁱ   St Clair, E William ^j   Fessler, Barri J ^l   Ding, Linna ^e   Viviano, Lisa ^e   Tchao, Nadia K ^f   Phippard, Deborah J ^f   Asare, Adam L ^f   Lim, Noha ^f   Ikle, David ^k   Jepson, Brett ^k   Brunetta, Paul ^m   Allen, Nancy B ^j   Fervenza, Fernando C ^a   Geetha, Duvuru ^d   Keogh, Karina ^a   Kissin, Eugene Y ^b   Monach, Paul A ^b   Peikert, Tobias ^a   Stegeman, Coen ⁱ   Ytterberg, Steven R ^a   Mueller, Mark ^e   Sejismundo, Lourdes P ^d   Mieras, Kathleen ^a   Stone, John H ^c   more..

^a MAYO CLINIC   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Immune Tolerance Network   (United States)

^g HOSPITAL FOR SPECIAL SURGERY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF GRONINGEN   (Netherlands)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k Rho   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PLACEBO; RITUXIMAB;

ADVERSE OUTCOME; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; TREATMENT DURATION;

EID: 84880882979     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1213277     Document Type: Article

References (36)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92. (Pubitemid 24065492)
2. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120(7):e9-e14.
3. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
4. Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
5. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
6. Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66.
7. Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
8. Specks U, Merkel PA, Hoffman GS, et al. Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial. Open Arthritis J 2011;4:1-18.
9. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44:912-20. (Pubitemid 32319784)
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
11. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80. (Pubitemid 27114101)
12. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-12. (Pubitemid 28527145)
13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.3 (http://ctep.cancer.gov/protocoldevelopment/electronic- applications/docs/ctcaev3.pdf).
14. Damoiseaux J, Dähnrich C, Rosemann A, et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic anti-body-associated vasculitis. Ann Rheum Dis 2009;68:228-33.
15. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoanti-body-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9. (Pubitemid 26067089)
16. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998;244:209-16. (Pubitemid 28389657)
17. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
18. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84. (Pubitemid 36396745)
19. Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
20. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): tenyear experience at a single center. Arthritis Rheum 2012;64:3770-8.
21. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9.
22. Hurd ER, Giuliano VJ. The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum 1975;18:67-75.
23. Stevenson HC, Fauci AS. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980;39: 391-7. (Pubitemid 10120785)
24. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453-7. (Pubitemid 12124460)
25. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987;79:1082-90. (Pubitemid 17065486)
26. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999;103: 885-94. (Pubitemid 29297593)
27. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40. (Pubitemid 34016203)
28. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic anti-body-associated vasculitis. Arthritis Rheum 2005;52:262-8. (Pubitemid 40129256)
29. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, openlabel pilot trial. Am J Respir Crit Care Med 2006;173:180-7. (Pubitemid 43187890)
30. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-73. (Pubitemid 30327189)
31. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
32. Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
33. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
34. Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
35. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
36. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8.